Format
Sort by
Items per page

Send to

Choose Destination

Best matches for O’Meara E[au]:

Search results

Items: 1 to 50 of 172

1.

Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.

Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD; PARAGON-HF Investigators.

J Am Coll Cardiol. 2019 Dec 10;74(23):2858-2873. doi: 10.1016/j.jacc.2019.09.063.

PMID:
31806129
2.

Cardiac remodelling patterns and proteomics: the keys to move beyond ejection fraction in heart failure?

O'Meara E, Allen BG.

Eur J Heart Fail. 2019 Nov 28. doi: 10.1002/ejhf.1691. [Epub ahead of print] No abstract available.

PMID:
31782231
3.

Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.

Vardeny O, Claggett B, Vaduganathan M, Beldhuis I, Rouleau J, O'Meara E, Anand IS, Shah SJ, Sweitzer NK, Fang JC, Desai AS, Lewis EF, Pitt B, Pfeffer MA, Solomon SD; TOPCAT Investigators.

JACC Heart Fail. 2019 Dec;7(12):1022-1028. doi: 10.1016/j.jchf.2019.08.019.

PMID:
31779923
4.

Screening mammography outcomes: risk of breast cancer and mortality by comorbidity score and age.

Demb J, Abraham L, Miglioretti DL, Sprague BL, O'Meara ES, Advani S, Henderson LM, Onega T, Buist DSM, Schousboe JT, Walter LC, Kerlikowske K, Braithwaite D.

J Natl Cancer Inst. 2019 Sep 6. pii: djz172. doi: 10.1093/jnci/djz172. [Epub ahead of print]

PMID:
31593591
5.

Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.

Bouabdallaoui N, O'Meara E, Bernier V, Komajda M, Swedberg K, Tavazzi L, Borer JS, Bohm M, Ford I, Tardif JC.

ESC Heart Fail. 2019 Oct 8. doi: 10.1002/ehf2.12513. [Epub ahead of print]

6.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators.

N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.

PMID:
31535829
7.

2017 Guidelines for the management of heart failure by pharmacists.

Beique LC, Ezekowitz JA, O'Meara E, McDonald M, Koshman SL.

Can Pharm J (Ott). 2019 Jul 2;152(5):301-316. doi: 10.1177/1715163519853307. eCollection 2019 Sep-Oct. No abstract available.

8.

A Randomized Trial of External Practice Support to Improve Cardiovascular Risk Factors in Primary Care.

Parchman ML, Anderson ML, Dorr DA, Fagnan LJ, O'Meara ES, Tuzzio L, Penfold RB, Cook AJ, Hummel J, Conway C, Cholan R, Baldwin LM.

Ann Fam Med. 2019 Aug 12;17(Suppl 1):S40-S49. doi: 10.1370/afm.2407.

9.

Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.

Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Shah AM, Lewis EF, Rouleau J, Pitt B, Solomon SD.

Eur J Heart Fail. 2019 Oct;21(10):1288-1291. doi: 10.1002/ejhf.1542. Epub 2019 Jul 22. No abstract available.

PMID:
31332920
10.

Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction.

Minamisawa M, Seidelmann SB, Claggett B, Hegde SM, Shah AM, Desai AS, Lewis EF, Shah SJ, Sweitzer NK, Fang JC, Anand IS, O'Meara E, Rouleau JL, Pitt B, Solomon SD.

JACC Heart Fail. 2019 Aug;7(8):664-675. doi: 10.1016/j.jchf.2019.04.020. Epub 2019 Jul 10.

PMID:
31302049
11.

Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging.

Kerlikowske K, Sprague BL, Tosteson ANA, Wernli KJ, Rauscher GH, Johnson D, Buist DSM, Onega T, Henderson LM, O'Meara ES, Miglioretti DL.

JAMA Intern Med. 2019 Jul 1. doi: 10.1001/jamainternmed.2019.1758. [Epub ahead of print]

PMID:
31260054
12.

Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.

Zile MR, O'Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M, Rouleau J.

J Am Coll Cardiol. 2019 Feb 26;73(7):795-806. doi: 10.1016/j.jacc.2018.11.042.

PMID:
30784673
13.

Airborne metals and polycyclic aromatic hydrocarbons in relation to mammographic breast density.

White AJ, Weinberg CR, O'Meara ES, Sandler DP, Sprague BL.

Breast Cancer Res. 2019 Feb 13;21(1):24. doi: 10.1186/s13058-019-1110-7.

14.

Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?

Korol S, White M, O'Meara E, Rouleau JL, White-Guay B, Dorais M, Ahmed A, de Denus S, Perreault S.

Eur J Clin Pharmacol. 2019 Jun;75(6):837-847. doi: 10.1007/s00228-018-02615-8. Epub 2019 Feb 13.

PMID:
30758517
15.

Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.

Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O'Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS.

JACC Heart Fail. 2019 Jan;7(1):25-32. doi: 10.1016/j.jchf.2018.10.017.

PMID:
30606484
16.

Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.

Myhre PL, O'Meara E, Claggett BL, de Denus S, Jarolim P, Anand IS, Beldhuis IE, Fleg JL, Lewis E, Pitt B, Rouleau JL, Solomon SD, Pfeffer MA, Desai AS.

Circ Heart Fail. 2018 Nov;11(11):e005312. doi: 10.1161/CIRCHEARTFAILURE.118.005312.

PMID:
30571192
17.

Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O'Meara E, Desai AS, Lewis EF, Pitt B, Sweitzer NK, Fang JC, Pfeffer MA, Solomon SD.

Circ Heart Fail. 2018 Nov;11(11):e005288. doi: 10.1161/CIRCHEARTFAILURE.118.005288.

18.

The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols.

FitzGerald TJ, Bishop-Jodoin M, Laurie F, O'Meara E, Davis C, Bogart J, Kalapurakal J, Siegel MJ, Chakravarthy B, Okunieff P, Haffty B, Michalski J, Ulin K, Followill DS, Kry S, Knopp M, Zhang J, Rosen D, Rosen M, Xiao Y, Schwartz L, Moni J, Cicchetti MG.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):775-782. doi: 10.1016/j.ijrobp.2018.08.039. Epub 2018 Oct 18. Review.

19.

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update.

Tobe SW, Stone JA, Anderson T, Bacon S, Cheng AYY, Daskalopoulou SS, Ezekowitz JA, Gregoire JC, Gubitz G, Jain R, Keshavjee K, Lindsay P, L'Abbe M, Lau DCW, Leiter LA, O'Meara E, Pearson GJ, Rabi DM, Sherifali D, Selby P, Tu JV, Wharton S, Walker KM, Hua-Stewart D, Liu PP.

CMAJ. 2018 Oct 9;190(40):E1192-E1206. doi: 10.1503/cmaj.180194. No abstract available.

20.

The Effect of Digital Breast Tomosynthesis Adoption on Facility-Level Breast Cancer Screening Volume.

Lee CI, Zhu W, Onega TL, Germino J, O'Meara ES, Lehman CD, Henderson LM, Haas JS, Kerlikowske K, Sprague BL, Rauscher GH, Tosteson ANA, Alford-Teaster J, Wernli KJ, Miglioretti DL.

AJR Am J Roentgenol. 2018 Nov;211(5):957-963. doi: 10.2214/AJR.17.19350. Epub 2018 Sep 20.

21.

Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.

Bouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O'Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL; PARADIGM-HF Investigators and Committees.

Eur J Heart Fail. 2018 Dec;20(12):1701-1709. doi: 10.1002/ejhf.1301. Epub 2018 Sep 11.

22.

Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.

Myhre PL, Vaduganathan M, Claggett BL, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD.

JAMA Cardiol. 2018 Oct 1;3(10):1000-1005. doi: 10.1001/jamacardio.2018.2568.

23.

Delirium After Cardiac Surgery and Cumulative Fluid Balance: A Case-Control Cohort Study.

Mailhot T, Cossette S, Lambert J, Beaubien-Souligny W, Cournoyer A, O'Meara E, Maheu-Cadotte MA, Fontaine G, Bouchard J, Lamarche Y, Benkreira A, Rochon A, Denault A.

J Cardiothorac Vasc Anesth. 2019 Jan;33(1):93-101. doi: 10.1053/j.jvca.2018.07.012. Epub 2018 Aug 17.

PMID:
30122614
24.

A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.

Korol S, White M, O'Meara E, Tournoux F, Racine N, Ducharme A, Rouleau JL, Liszkowski M, Mansour A, Jutras M, Guertin MC, Bernier M, Lavoie J, Leclair G, Neagoe PE, Chaar D, Sirois MG, de Denus S.

Am Heart J. 2018 Oct;204:190-195. doi: 10.1016/j.ahj.2018.07.002. Epub 2018 Jul 10.

PMID:
30097164
25.

Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.

Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, Anand IS, O'Meara E, Rouleau JL, Sweitzer NK, Fang JC, Saksena S, Pitt B, Pfeffer MA, Solomon SD.

JACC Heart Fail. 2018 Aug;6(8):689-697. doi: 10.1016/j.jchf.2018.05.005. Epub 2018 Jul 11.

26.

Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.

Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV.

Circ Heart Fail. 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.

PMID:
29980595
27.

Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).

O'Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang LM, Solomon SD, Packer M, McMurray JJV, Zile MR.

Circ Heart Fail. 2018 May;11(5):e004446. doi: 10.1161/CIRCHEARTFAILURE.117.004446.

PMID:
29748349
28.

A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure.

de Denus S, Dubé MP, Fouodjio R, Huynh T, LeBlanc MH, Lepage S, Sheppard R, Giannetti N, Lavoie J, Mansour A, Provost S, Normand V, Mongrain I, Langlois M, O'Meara E, Ducharme A, Racine N, Guertin MC, Turgeon J, Phillips MS, Rouleau JL, Tardif JC, White M; CANDIID II investigators.

Pharmacogenomics. 2018 May;19(7):599-612. doi: 10.2217/pgs-2018-0004. Epub 2018 Apr 27.

PMID:
29701105
29.

Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.

Lewis EF, Claggett B, Shah AM, Liu J, Shah SJ, Anand I, O'Meara E, Sweitzer NK, Rouleau JL, Fang JC, Desai AS, Retta TM, Solomon SD, Heitner JF, Stamos TD, Boineau R, Pitt B, Pfeffer MA.

Circ Heart Fail. 2018 Mar;11(3):e004457. doi: 10.1161/CIRCHEARTFAILURE.117.004457.

PMID:
29664406
30.

Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.

Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, McKinlay S, O'Meara E, Shah SJ, Sweitzer NK, Solomon S, Pitt B.

J Card Fail. 2018 May;24(5):313-320. doi: 10.1016/j.cardfail.2018.03.002. Epub 2018 Mar 20.

PMID:
29572190
31.

Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial.

Vaduganathan M, Claggett BL, Chatterjee NA, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Hegde SM, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD.

JACC Heart Fail. 2018 Aug;6(8):653-661. doi: 10.1016/j.jchf.2018.02.014. Epub 2018 Mar 4.

32.

Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer.

Buist DSM, Abraham L, Lee CI, Lee JM, Lehman C, O'Meara ES, Stout NK, Henderson LM, Hill D, Wernli KJ, Haas JS, Tosteson ANA, Kerlikowske K, Onega T; Breast Cancer Surveillance Consortium.

JAMA Intern Med. 2018 Apr 1;178(4):458-468. doi: 10.1001/jamainternmed.2017.8549.

33.

Underutilization of Supplemental Magnetic Resonance Imaging Screening Among Patients at High Breast Cancer Risk.

Miles R, Wan F, Onega TL, Lenderink-Carpenter A, O'Meara ES, Zhu W, Henderson LM, Haas JS, Hill DA, Tosteson ANA, Wernli KJ, Alford-Teaster J, Lee JM, Lehman CD, Lee CI.

J Womens Health (Larchmt). 2018 Jun;27(6):748-754. doi: 10.1089/jwh.2017.6623. Epub 2018 Jan 17.

34.

Dysregulated mitogen-activated protein kinase signalling as an oncogenic basis for clear cell sarcoma of the kidney.

Kenny C, McDonagh N, Lazaro A, O'Meara E, Klinger R, O'Connor D, Roche F, Hokamp K, O'Sullivan MJ.

J Pathol. 2018 Mar;244(3):334-345. doi: 10.1002/path.5020. Epub 2018 Jan 23.

PMID:
29243812
35.

2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure.

Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, Giannetti N, Grzeslo A, Hamilton PG, Heckman GA, Howlett JG, Koshman SL, Lepage S, McKelvie RS, Moe GW, Rajda M, Swiggum E, Virani SA, Zieroth S, Al-Hesayen A, Cohen-Solal A, D'Astous M, De S, Estrella-Holder E, Fremes S, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, LeBlanc MH, Masoudi FA, Ross HJ, Roussin A, Sussex B.

Can J Cardiol. 2017 Nov;33(11):1342-1433. doi: 10.1016/j.cjca.2017.08.022. Epub 2017 Sep 6.

PMID:
29111106
36.

Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction.

Bajaj NS, Claggett B, Lewis EF, Desai AS, Fang JC, O'Meara E, Shah SJ, Sweitzer NK, Fleg JL, Pitt B, Rouleau JL, Finn P, Pfeffer MA, Solomon SD.

Eur J Heart Fail. 2018 Apr;20(4):815-816. doi: 10.1002/ejhf.1040. Epub 2017 Oct 25. No abstract available.

37.

Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study.

Sanders JL, Guo W, O'Meara ES, Kaplan RC, Pollak MN, Bartz TM, Newman AB, Fried LP, Cappola AR.

J Gerontol A Biol Sci Med Sci. 2018 Jun 14;73(7):953-959. doi: 10.1093/gerona/glx143.

38.

N-Terminal Pro B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T Levels Are Related to the Extent of Hibernating Myocardium in Patients With Ischemic Heart Failure.

Zelt JGE, Liu PP, Erthal F, deKemp RA, Wells G, O'Meara E, Garrard L, Beanlands RSB, Mielniczuk LM.

Can J Cardiol. 2017 Nov;33(11):1478-1488. doi: 10.1016/j.cjca.2017.06.012. Epub 2017 Jun 27.

PMID:
28966019
39.

Impact of Left Ventricular vs Biventricular Pacing on Reverse Remodelling: Insights From the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) Trial.

Skaf S, Thibault B, Khairy P, O'Meara E, Fortier A, Vakulenko HV, Pitre C, White M, Ducharme A; EARTH Investigators.

Can J Cardiol. 2017 Oct;33(10):1274-1282. doi: 10.1016/j.cjca.2017.07.478. Epub 2017 Jul 31.

PMID:
28941607
40.

Parental awareness of schoolbag carriage: A comparative study of Irish and United States parents.

Dockrell S, Jacobs K, Byrne J, Gleeson E, Kelly S, Moore C, O'Meara E, Barclay D, Rodriguez S, Kang D, Simms C, Blake C.

Work. 2017;58(2):85-93. doi: 10.3233/WOR-172605.

PMID:
28922183
41.

Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.

de Denus S, O'Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL.

N Engl J Med. 2017 Apr 27;376(17):1690-1692. doi: 10.1056/NEJMc1612601. No abstract available.

42.

Association between air pollution and mammographic breast density in the Breast Cancer Surveilance Consortium.

Yaghjyan L, Arao R, Brokamp C, O'Meara ES, Sprague BL, Ghita G, Ryan P.

Breast Cancer Res. 2017 Apr 6;19(1):36. doi: 10.1186/s13058-017-0828-3.

43.

Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.

Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O'Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD.

JACC Heart Fail. 2017 Apr;5(4):241-252. doi: 10.1016/j.jchf.2016.11.015.

44.

Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.

Hawkins NM, Jhund PS, Pozzi A, O'Meara E, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, Virani S, McMurray JJ.

Eur J Heart Fail. 2016 Sep;18(9):1162-71. doi: 10.1002/ejhf.614.

45.

Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology.

Cushman M, O'Meara ES, Heckbert SR, Zakai NA, Rosamond W, Folsom AR.

Thromb Res. 2016 Aug;144:127-32. doi: 10.1016/j.thromres.2016.06.012. Epub 2016 Jun 15.

46.

Multilevel factors associated with long-term adherence to screening mammography in older women in the U.S.

Hubbard RA, O'Meara ES, Henderson LM, Hill D, Braithwaite D, Haas JS, Lee CI, Sprague BL, Alford-Teaster J, Tosteson ANA, Wernli KJ, Onega T.

Prev Med. 2016 Aug;89:169-177. doi: 10.1016/j.ypmed.2016.05.034. Epub 2016 May 31.

47.

Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC.

Giaddui T, Chen W, Yu J, Lin L, Simone CB 2nd, Yuan L, Gong YU, Wu QJ, Mohan R, Zhang X, Bluett JB, Gillin M, Moore K, O'Meara E, Presley J, Bradley JD, Liao Z, Galvin J, Xiao Y.

Radiat Oncol. 2016 May 4;11:66. doi: 10.1186/s13014-016-0640-8.

48.

Structures' validation profiles in Transmission of Imaging and Data (TRIAD) for automated National Clinical Trials Network (NCTN) clinical trial digital data quality assurance.

Giaddui T, Yu J, Manfredi D, Linnemann N, Hunter J, O'Meara E, Galvin J, Bialecki B, Xiao Y.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):331-333. doi: 10.1016/j.prro.2016.01.007. Epub 2016 Jan 21.

49.

QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.

Joseph J, Claggett BC, Anand IS, Fleg JL, Huynh T, Desai AS, Solomon SD, O'Meara E, Mckinlay S, Pitt B, Pfeffer MA, Lewis EF.

JACC Heart Fail. 2016 Jun;4(6):477-86. doi: 10.1016/j.jchf.2016.02.013. Epub 2016 Mar 30.

50.

Ivabradine for the treatment of chronic heart failure.

Henri C, O'Meara E, De Denus S, Elzir L, Tardif JC.

Expert Rev Cardiovasc Ther. 2016;14(5):553-61. doi: 10.1586/14779072.2016.1165092. Epub 2016 Mar 28. Review.

PMID:
26967048

Supplemental Content

Loading ...
Support Center